



**GENPHARMASEC
LIMITED**

CIN : L24231MH1992PLC323914

(Formerly known as Generic Pharmasec Limited)



Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises
Co-Operative Society Ltd., Akurli Road, Kandivali (East),
Mumbai, Maharashtra, 400101



+91- 86555 50242



compliance@genpharmasec.com
info@genpharmasec.com



www.genpharmasec.com

Date: 14th February 2022

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited,
14th Floor, P.J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sir/ Madam,

**Subject:- Outcome of Board Meeting held on Monday, 14th February, 2022
at 05.00 P. M.**

Reference: BSE Scrip Code: 531592

Pursuant to the provisions of Regulation 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors of our Company in their meeting held on Monday, 14th February 2022 has inter alia:

1. Considered and Approved and taken on records the Un-Audited Financial Results along with Limited Review Report for the Quarter and Nine Months ended 31st December, 2021 prepared in terms of IND-AS, pursuant to Regulation 33 of (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Approved Resignation of Mr. Vivek Anand Oberoi, from the post of Chief Strategy Officer (CSO) of the Company w.e.f February 14, 2022 due to his pre- occupation in other assignments.

Kindly take the same on your records.

Thanking You,

Yours Truly,

**For Genpharmasec Limited
(Formerly Known as Generic Pharmasec Limited)**

Ulhas Narayan Deosthale
Whole Time Director & CFO
DIN: 09215291



GENPHARMASEC LIMITED (FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)

Statement of Standalone Unaudited Financial Results for the Quarter & Nine Month Ended December 31, 2021

(Rs. In Lakhs)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from Operations	676.01	501.90	241.50	1,988.19	1,454.66	2,130.75
2 Other Income	1.60	0.65	8.30	8.12	38.27	32.78
3 Total Revenue (1 + 2)	677.61	502.55	249.79	1,996.31	1,492.93	2,163.53
4 Expenses						
Purchase of stock-in-trade	591.98	426.12	393.05	2,130.66	1,521.69	2,342.12
Changes in inventories of finished goods, work-in-progress and stock-in-trade	25.86	112.76	(172.33)	(203.62)	4.53	(422.08)
Employee benefits expense	6.31	5.06	5.04	15.69	13.81	18.75
Depreciation and amortisation expense	0.36					
Other expenses	31.07	24.89	21.32	77.49	62.91	72.54
Total expenses	655.57	569.14	247.41	2,021.23	1,603.85	2,012.58
5 Profit/(Loss) Before Exceptional Item and Tax (3-4)	22.03	(66.59)	2.38	(24.92)	(110.92)	150.95
6 Exceptional Items	-	-	-	-	-	-
7 Profit/(Loss) Before Tax (5-6)	22.03	(66.59)	2.38	(24.92)	(110.92)	150.95
8 Tax expense						
(1) Current Tax	-	(5.11)	-	-	-	25.20
(2) Deferred Tax	-	-	-	-	-	(0.10)
9 Profit / (Loss) from continuing operations (7 - 8)	22.03	(61.48)	2.38	(24.92)	(110.92)	125.86
10 Profit / (Loss) from discontinuing operations	-	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-	-
12 Profit/(loss) from Discontinuing operations (after tax)	-	-	-	-	-	-
13 Profit (Loss) for the period (9+12)	22.03	(61.48)	2.38	(24.92)	(110.92)	125.86
14 Other Comprehensive income:						
A (i) Items that will not be reclassified to profit or loss	(164.69)	(124.21)	(138.60)	(392.04)	(170.79)	(413.04)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
15 Total Comprehensive Income for the period (13+14) (Comprising profit/ (loss) and other Comprehensive Income for the period	(142.66)	(185.69)	(136.22)	(416.97)	(281.72)	(287.19)
16 Earnings per equity share (for discontinued & continuing operations) of face value of Rs. 10 each						
(a) Basic	0.01	(0.02)	0.00	(0.01)	(0.04)	0.05
(b) Diluted	0.01	(0.02)	0.00	(0.01)	(0.04)	0.05

Notes:

- The above result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 14th February, 2022.
- The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- Previous period figures have been regrouped/reclassified as considered necessary to facilitate comparison.
- The Financial results for the quarter & nine months ended on 31st December, 2021 have been subjected to a "Limited Review" by the statutory auditors of the Company. The Limited review report does not contain any qualification. The Limited review report will be filed with the stock Exchange and will also be available on Company's website www.welconinternational.com
- Segment Reporting has been annexed in Annexure 1.
- The certificate of CFO in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the above results has been placed before the Board of Directors
- The interest income of Rs.1.21 Lacs on loans of Rs. 68.07 Lacs given by the company have not been accounted for the quarter ended December, 2021 as the respective parties are renegotiating the rate of interest due to CoVid-19 pandemic. The effect of renegotiation on interest income will be accounted in the last quarter ended March, 2022.
- The figures for the quarter ended 31st December, 2021 as reported in the financial result, are the balancing figures between nine months ended 31st December, 2021 . The Financial results for the quarter & nine months ended ended on 31st December, 2021 have been subjected to a "Limited Review" by the statutory auditors of the Company.

For and on behalf of the Board of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)



Udeshale
(Ulhas Narayan Deosthale)
Director & CFO
Din : 09215291

PLACE : MUMBAI
DATE :14.02.2022

GENPHARMASEC LIMITED (FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)

"ANNEXURE - I"

Statement of Segment-wise Revenue, Results, Assets and Liabilities for the Quarter & Nine Months Ended 31st December, 2021

(Rs. In Lakhs)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Segment Revenue						
Pharmaceuticals	676.01	474.55	222.26	1,945.99	1,435.42	2,079.93
Trading in Securities	-	27.35	19.24	42.20	19.24	50.40
Total Revenue	676.01	501.90	241.50	1,988.19	1,454.66	2,130.34
Segment Results (Profit before tax and interest)						
Pharmaceuticals	148.71	46.39	16.42	265.28	116.62	236.58
Trading in Securities	(114.64)	(97.09)	(0.74)	(264.21)	(0.74)	(53.75)
Total	34.07	(50.70)	15.68	1.07	115.88	182.83
Less						
(i) Unallocated Finance Cost	-	-	-	-	-	-
(ii) Other unallocable expenditure net of unallocable income	12.04	(15.90)	13.30	25.99	226.80	(64.98)
(iii) Inter Segment Eliminations	-	-	-	-	-	-
Profit Before Tax	22.03	(34.80)	2.38	(24.92)	(110.92)	247.81
Segment Assets						
Pharmaceuticals	1,333.72	1,140.96	837.67	1,333.72	837.67	1,310.96
Trading in Securities	311.69	426.78	296.18	311.69	296.18	340.11
Un-Allocated	616.98	826.96	1,454.36	616.98	1,454.36	1,130.89
Total	2,262.39	2,394.70	2,588.21	2,262.39	2,588.21	2,781.96
Segment Liabilities						
Pharmaceuticals	562.08	601.40	294.48	562.08	294.48	711.61
Trading in Securities	-	-	-	-	-	-
Un-Allocated	1,700.31	1,793.30	2,293.73	1,700.31	2,293.73	2,070.34
Total	2,262.39	2,394.70	2,588.21	2,262.39	2,588.21	2,781.96
	-	-	-	-	-	-

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).

For and on behalf of the Board of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)



Ulhas Narayan Deosthale
(Ulhas Narayan Deosthale)
Director & CFO
Din : 09215291

PLACE : MUMBAI
DATE :14.02.2022




Independent Auditor's Review Report on Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
Board of Directors of
GENERIC PHARMASEC LIMITED

We have reviewed the accompanying statement of unaudited financial results of **GENERIC PHARMASEC LIMITED** for the quarter ended 31st December, 2021 and for nine months period from 1st April, 2021 to 31st December, 2021 ('the Statement') attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

01. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rule, 2015, as amended and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
02. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
03. As stated in Note 7, the interest income of Rs. 1.21 Lacs on loans of Rs. 68.07 Lacs given by the company have not been accounted for the quarter ended December, 2021 due to renegotiation of rate of interest with respective parties due to Covid-19 pandemic. The profit before tax for the quarter ended and nine months ended December, 2021 is shown less to that extent subject to renegotiation.
04. Based on our review conducted as above subject to point no 4 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Indian accounting Standards ('Ind AS') prescribed under s.133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Abhishek S Tiwari & Associates
Chartered Accountants


Abhishek Tiwari
Partner

M.No.155947
Place : Mumbai
Date: 14.02.2022

UDIN: 22155947ABYXOV3453

